← Back to overview
Brochure

Don't be Fooled by your Full

Download here →
Did you know that “true full” therapeutic vector genomes are often the minority in recombinant adeno-associated virus (rAAV) populations for gene therapy, perhaps more so than current analytical methods reveal?

Highlights

Low amounts of rAAVs with full transgene payloads can negatively impact process efficiency, and product efficacy. This could lead to higher manufacturing costs, suboptimal quality of  end products, and higher dosage for patients potentially increasing safety risk profiles.

Current methods to analyze transgenes fail to accurately quantify full-length versus truncated transgenes.

This can compound problems in manufacturing pipelines as rAAV gene therapy requires high yields of high-quality vectors manufactured at lower costs.

Complete the form to download & receive the white paper by email.

‍

← Back to overview
Brochure

Don't be Fooled by your Full

Did you know that “true full” therapeutic vector genomes are often the minority in recombinant adeno-associated virus (rAAV) populations for gene therapy, perhaps more so than current analytical methods reveal?
Download here →

Highlights

Low amounts of rAAVs with full transgene payloads can negatively impact process efficiency, and product efficacy. This could lead to higher manufacturing costs, suboptimal quality of  end products, and higher dosage for patients potentially increasing safety risk profiles.

Current methods to analyze transgenes fail to accurately quantify full-length versus truncated transgenes.

This can compound problems in manufacturing pipelines as rAAV gene therapy requires high yields of high-quality vectors manufactured at lower costs.

Complete the form to download & receive the white paper by email.

‍